Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Acquires Epinomics

NEW YORK (GenomeWeb) – 10x Genomics said on Tuesday that it has acquired Epinomics, a startup that spun out of Stanford University to commercialize technology for mapping chromatin regions across the genome.

Epinomics has been developing its technology for clinical applications, including using epigenomic signatures to predict response to immunotherapy. It has a collaboration with Stanford's Park Institute for Cancer Immunotherapy to use biomarkers and epigenomics technology to improve cancer immunotherapies.

Privately held 10x Genomics plans to integrate Epinomics' ATAC-seq epigenetic technology onto its Chromium system and plans to launch a single-cell ATAC solution by the end of the year.

"Today's acquisition gives us a strong team, IP, and technology that has been enthusiastically validated by customers," 10x Genomics CEO Serge Saxonov said in a statement. "It provides a foundation for powerful new products and positions us well to become the leader in epigenomics."

Financial terms of the acquisition were not disclosed. Epinomics is backed by venture firms including Lightspeed Venture Partners, Felicis Ventures, and Founders Fund.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.